作者
Mendel Goldfinger,Ioannis Mantzaris,Aditi Shastri,Yogen Saunthararajah,Kira Gritsman,R. Alejandro Sica,Noah Kornblum,Nishi Shah,David Levitz,Bradley Rockwell,Lauren C. Shapiro,Ridhi Gupta,Kith Pradhan,Xiaonan Xue,Anne Munoz,Aradhika Dhawan,Karen Fehn,Monica Comas,Jhannine Alyssa Verceles,Brian A. Jonas,Suman Kambhampati,Yang Shi,Ira Braunschweig,Dennis Cooper,Marina Konopleva,Eric J. Feldman,Amit Verma
摘要
A metronomic, low-dose schedule of decitabine and Venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median OS for AML and TP53 mutated patients was 16.1 and 11.3 months respectively.
爱静静
加菲丰丰
有人
shinysparrow
寻道图强
可口可乐了
乐乐乐乐乐乐
景辣条
充电宝
精明元霜
mmyhn
sirius
AireenBeryl531
星辰大海
kento
morena
丘比特
浅尝离白
Singularity
从容芮
皖公网安备34019202002308
